GPT and pneumonia: Four patients discontinued treatment due to G3 TRAEs (one G3 pneumonia in inetetamab with 240 mg pyrotinib group, two G3 diarrhea, and one G3 increased ALT/aspartate aminotransferase [AST] in inetetamab with 320 mg pyrotinib group).